Pharming Group N.V. (PHAR) Q3 2024 Earnings
PHAR·Reported October 24, 2024·Before market open
Pharming Group N.V. reported Q3 2024 revenue of $83.8M, beat analyst consensus of $75.6M by $8.3M. Diluted EPS came in at $-0.02, missed the $0.01 consensus by $0.03.
Revenue
$83.8Mbeat by $8.3M
Consensus: $75.6MDiluted EPS
$-0.02missed by $0.03
Consensus: $0.01
SEC Filings
Earnings release8-K not filed yet
Quarterly report10-Q / 10-K not filed yet
Filings will appear here once submitted to SEC EDGAR.
Q3 2024 Earnings FAQ
Common questions about Pharming Group N.V.'s Q3 2024 earnings report.
Pharming Group N.V. (PHAR) reported Q3 2024 earnings on October 24, 2024 before market open.
Pharming Group N.V. reported revenue of $83.8M and diluted EPS of $-0.02 for Q3 2024.
Revenue beat the consensus estimate of $75.6M by $8.3M. EPS missed the consensus estimate of $0.01 by $0.03.